Brain+ A/S: Pioneering Cognitive Care in the UK Market
September 19, 2024, 4:18 am
In the realm of healthcare, innovation is the lifeblood that keeps systems alive. Brain+ A/S, a Danish healthtech company, is poised to inject new energy into dementia care in the UK. With its upcoming launch of the CST-Assistant, the company aims to tap into a market that is ripe for change. The goal? To achieve recurring revenue of DKK 7-8 million by 2025 and scale up to DKK 25-27 million by 2027.
Dementia is a growing concern, affecting nearly one million people in the UK. It’s a silent storm, wreaking havoc on families and the healthcare system alike. The introduction of Cognitive Stimulation Therapy (CST) offers a beacon of hope. CST has shown the ability to delay cognitive decline by six months, enhancing the quality of life for those affected. Yet, despite its potential, CST remains underutilized. Barriers such as resource limitations and logistical challenges have hindered its widespread adoption.
The UK’s National Health Service (NHS) has recently taken steps to address these issues. New Right Care guidelines emphasize the importance of evidence-based interventions like CST. This shift in policy creates a fertile ground for Brain+ to introduce its CST-Assistant. The product is not just another tool; it’s a lifeline designed to standardize and scale CST delivery across the UK.
The CST-Assistant is set to launch at the end of September 2024. It’s a Medical Device Software that has already undergone validation in clinical trials. The trials, conducted at two AgeUK sites, confirmed its product-market fit. The response from potential customers has been overwhelmingly positive, indicating a pressing need for solutions that facilitate CST adoption.
Brain+ has assembled a robust commercial team to spearhead its UK strategy. Led by Devika Wood, the new Chief Commercial Officer, the team boasts a strong track record in healthtech sales. They are not just selling a product; they are championing a cause. The aim is to reach out to 104 NHS services that are primed for CST adoption. These institutions have been carefully selected based on their existing CST offerings, digital health adoption, and dedicated dementia care strategies.
The commercial plan is ambitious yet achievable. It includes a series of milestones designed to build momentum. In September, Brain+ will launch a branding and awareness campaign to highlight its unique approach to CST. Following this, the CST-Assistant will be introduced to key stakeholders within the NHS. By October, a white paper will be published, detailing the benefits of the CST-Assistant and addressing current barriers to adoption.
The path to success is paved with challenges. Funding will play a crucial role in Brain+’s ability to execute its commercial plan. The company aims to break even by late 2026, but this will depend on securing the necessary financial resources. However, the potential rewards are significant. With a growing market for dementia care solutions, Brain+ is positioned to make a substantial impact.
Sales projections are optimistic. For 2024, the company anticipates closing early NHS contracts worth DKK 0.15-0.2 million. By 2025, they aim to reach DKK 7-8 million in recurring revenue, with further growth expected in subsequent years. The introduction of additional CST products in 2025 and 2026 will further enhance their offerings, allowing for remote therapy delivery and interaction with patients at home.
The landscape of dementia care is changing. With the NHS ready to embrace CST, Brain+ is at the forefront of this transformation. The CST-Assistant is not just a product; it’s a promise of better care for those living with dementia. As the company prepares for its UK launch, it embodies the spirit of innovation and resilience.
In conclusion, Brain+ A/S is not merely entering the UK market; it is setting the stage for a revolution in dementia care. With a clear vision, a validated product, and a dedicated team, the company is ready to tackle the challenges ahead. The journey may be fraught with obstacles, but the potential to improve lives makes it a worthy endeavor. As Brain+ moves forward, it carries the hopes of many, illuminating the path toward a brighter future for dementia care in the UK.
Dementia is a growing concern, affecting nearly one million people in the UK. It’s a silent storm, wreaking havoc on families and the healthcare system alike. The introduction of Cognitive Stimulation Therapy (CST) offers a beacon of hope. CST has shown the ability to delay cognitive decline by six months, enhancing the quality of life for those affected. Yet, despite its potential, CST remains underutilized. Barriers such as resource limitations and logistical challenges have hindered its widespread adoption.
The UK’s National Health Service (NHS) has recently taken steps to address these issues. New Right Care guidelines emphasize the importance of evidence-based interventions like CST. This shift in policy creates a fertile ground for Brain+ to introduce its CST-Assistant. The product is not just another tool; it’s a lifeline designed to standardize and scale CST delivery across the UK.
The CST-Assistant is set to launch at the end of September 2024. It’s a Medical Device Software that has already undergone validation in clinical trials. The trials, conducted at two AgeUK sites, confirmed its product-market fit. The response from potential customers has been overwhelmingly positive, indicating a pressing need for solutions that facilitate CST adoption.
Brain+ has assembled a robust commercial team to spearhead its UK strategy. Led by Devika Wood, the new Chief Commercial Officer, the team boasts a strong track record in healthtech sales. They are not just selling a product; they are championing a cause. The aim is to reach out to 104 NHS services that are primed for CST adoption. These institutions have been carefully selected based on their existing CST offerings, digital health adoption, and dedicated dementia care strategies.
The commercial plan is ambitious yet achievable. It includes a series of milestones designed to build momentum. In September, Brain+ will launch a branding and awareness campaign to highlight its unique approach to CST. Following this, the CST-Assistant will be introduced to key stakeholders within the NHS. By October, a white paper will be published, detailing the benefits of the CST-Assistant and addressing current barriers to adoption.
The path to success is paved with challenges. Funding will play a crucial role in Brain+’s ability to execute its commercial plan. The company aims to break even by late 2026, but this will depend on securing the necessary financial resources. However, the potential rewards are significant. With a growing market for dementia care solutions, Brain+ is positioned to make a substantial impact.
Sales projections are optimistic. For 2024, the company anticipates closing early NHS contracts worth DKK 0.15-0.2 million. By 2025, they aim to reach DKK 7-8 million in recurring revenue, with further growth expected in subsequent years. The introduction of additional CST products in 2025 and 2026 will further enhance their offerings, allowing for remote therapy delivery and interaction with patients at home.
The landscape of dementia care is changing. With the NHS ready to embrace CST, Brain+ is at the forefront of this transformation. The CST-Assistant is not just a product; it’s a promise of better care for those living with dementia. As the company prepares for its UK launch, it embodies the spirit of innovation and resilience.
In conclusion, Brain+ A/S is not merely entering the UK market; it is setting the stage for a revolution in dementia care. With a clear vision, a validated product, and a dedicated team, the company is ready to tackle the challenges ahead. The journey may be fraught with obstacles, but the potential to improve lives makes it a worthy endeavor. As Brain+ moves forward, it carries the hopes of many, illuminating the path toward a brighter future for dementia care in the UK.